We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Results 1 to 5 of 6
Most popular |Most recent


Top Tips for Overcoming Section 103 Obviousness Rejections

USA - September 28 2018 Assuming novelty, the USPTO, PTAB, or a court must establish that the claimed invention would have been obvious over the prior art. In other words...

Thomas L. Irving.


An Issued Life Science MPF1 U.S. Patent Claim: Ex parte Gleave

USA - September 13 2018 25. (new) A pharmaceutical composition comprising a therapeutic agent effective to reduce the amount of active hsp27 in cancerous cells exposed to...

Thomas L. Irving.


Informative One Day, Non-Informative the Next

USA - August 31 2018 Jung argued that the claim was not obvious because the references did not teach at least one of a connection branch and at least one of a contents...

Thomas L. Irving.


How the PTAB and Federal Circuit Have Responded to Aqua Products

USA - March 28 2018 The patent bar watched the en banc rehearing decision in Aqua Products Inc. v. Matal, 872 F.3d 1290 (Fed. Cir. 2017), with great interest. This was...

Thomas L. Irving, Barbara Clarke McCurdy.


A Look at Chemical Supplemental Examination Requests

USA - January 25 2018 An effective litigation tool available that may be available to an accused infringer is the defense of inequitable conduct, which seeks to ensure...

Thomas L. Irving, Amanda K. Murphy.